Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Molecular Formula |
C18H34CLN2O8PS
|
---|---|
Molecular Weight |
504.95
|
Elemental Analysis |
C, 42.81; H, 6.79; Cl, 7.02; N, 5.55; O, 25.35; P, 6.13; S, 6.35
|
CAS # |
24729-96-2
|
Related CAS # |
Clindamycin hydrochloride;21462-39-5;Clindamycin palmitate hydrochloride;25507-04-4;Clindamycin;18323-44-9;Clindamycin phosphate hydrochloride;64023-51-4
|
Appearance |
White to off-white solid powder.
|
SMILES |
CCC[C@@H]1C[C@@H](C(N[C@H]([C@@H](Cl)C)[C@@H]2[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O2)=O)N(C)C1
|
InChi Key |
UFUVLHLTWXBHGZ-MGZQPHGTSA-N
|
InChi Code |
InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1
|
Chemical Name |
(2R,3R,4S,5R,6R)-6-((1S,2S)-2-chloro-1-((2S,4R)-1-methyl-4-propylpyrrolidine-2-carboxamido)propyl)-4,5-dihydroxy-2-(methylthio)tetrahydro-2H-pyran-3-yl
dihydrogen phosphate
|
Synonyms |
Cleocin T; Clinda-Derm; Clindagel; Evoclin; U 28508; U-28508; U28508
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : 100 mg/mL (198.04 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (99.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9804 mL | 9.9020 mL | 19.8039 mL | |
5 mM | 0.3961 mL | 1.9804 mL | 3.9608 mL | |
10 mM | 0.1980 mL | 0.9902 mL | 1.9804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The adjusted mean percentage reduction from baseline over 12 weeks in (a) total lesion (TL), (b) inflammatory lesion (IL) and (c) non‐IL counts. [2]. J Dermatol. 2018 Aug;45(8):951-962. td> |
Proportion of patients with (a) at least a two‐grade improvement in Investigator's Static Global Assessment (ISGA) score or (b) with an Investigator's Static Global Assessment (ISGA) score of 0 or 1 at each study visit. [2]. J Dermatol. 2018 Aug;45(8):951-962. td> |
Skindex‐16 assessment scores (a) total, (b) symptom, (c) emotion and (d) functioning domains.[2]. J Dermatol. 2018 Aug;45(8):951-962. td> |